CYP19A1 and breast cancer: Everolimus plus exemestane (a steroidal aromatase inhibitor) was approved in hormone-receptor-positive advanced breast cancer that had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor [5].